

Pharmaceuticals and Biotechnology

Drug companies face pressure from many directions – from a foreboding regulatory landscape, from competitors with alternative brands or generics, from insurers pushing back on prescription drug costs and reimbursement.

Whether you're a global pharmaceuticals company or a biotechnology startup, accomplishing business goals in such a highly regulated industry requires practical, integrated legal analysis and advice. At the same time, you can find opportunities in maximizing the benefits of statutes that encourage new drug development.

Representative experience

Novartis on the Series C investment in Pliant Therapeutics Inc., a company focused on discovering and developing novel therapies to slow or halt the progression of multiple fibrotic diseases.

Jazz Pharmaceuticals on the acquisition of Cavion, Inc. a company that creates therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.

Medigene AG in US\$1bn+ deal with bluebird bio to establish a strategic T cell receptor alliance in cancer immunotherapy.

Gilead Sciences on the technology license agreement with Xencor, Inc., a company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease,

Contacts

Philip Katz,
Washington, D.C.

Meredith Manning,
Washington, D.C.

Dr. Jörg Schickert,
Munich

Industries

Life Sciences and Health
Care

asthma, and allergic diseases.

Novartis on its US\$665m acquisition of Selexys Pharmaceuticals and with its landmark portfolio transformation transactions with GSK and Eli Lilly.

A leading Japanese innovator pharmaceutical firm in numerous Hatch-Waxman actions in relation to generic versions of its product.

DepoMed in patent suit and IPRs against Endo Pharmaceuticals relating to Opana® ER; PTAB upheld Depomed's patents on controlled release gastric retentive technology.

Merck Sharp & Dohme in Hatch-Waxman actions against Hospira and Sandoz in relation to Merck's antibiotic drug, Invanz®.

Serving as national product liability counsel for Bristol-Myers Squibb in a mass tort involving allegations that Abilify causes compulsion gambling.

A global pharmaceutical company on multijurisdictional personal injury litigation and coordinating the client's defense in more than 27 countries.

A biotechnology manufacturer in investigation of multiple whistleblower allegations that the company promoted a surgical implant for off-label use.

Conducted internal investigations at global pharmaceutical companies into allegations of money laundering, international corruption, and fraudulent practices related to asset transfers in multiple countries.

Latest thinking and events

Published Works

These Are The Top Priorities & Challenges For New CDER Director Patrizia Cavazzoni, M.D.

Life Sciences Connect

Published Works

2021 Chambers Global Practice Guide in Life Sciences

Chambers Global Practice Guide

[Hogan Lovells Publications](#)

Life sciences and health care horizons 2021

[Webinar](#)

Brexit and the pharmaceutical industry webinar

[Press Releases](#)

Hogan Lovells advises Novartis in respiratory cell therapy licensing deal with Mesoblast

[Hogan Lovells Publications](#)

Proposed measures in Germany for safeguarding supply of critical goods in the combat against COVID-19